Emory University Winship Cancer Institute: Multiple Myeloma Trial Provides First Randomized Evidence for Optimal Duration of Maintenance Therapy
July 18, 2026
July 18, 2026
ATLANTA, Georgia, July 18 -- Emory University Winship Cancer Institute issued the following news release:
* * *
Multiple myeloma trial provides first randomized evidence for optimal duration of maintenance therapy
Results of the randomized Phase 3 ENDURANCE clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), published in the New England Journal of Medicine, offer new insights into the optimal maintenance therapy strategy for patients with n . . .
* * *
Multiple myeloma trial provides first randomized evidence for optimal duration of maintenance therapy
Results of the randomized Phase 3 ENDURANCE clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), published in the New England Journal of Medicine, offer new insights into the optimal maintenance therapy strategy for patients with n . . .